| Literature DB >> 32810515 |
Matthew Greenhawt1, Marcus Shaker2, Julie Wang3, John J Oppenheimer4, Scott Sicherer3, Corinne Keet5, Keri Swaggart6, Matthew Rank7, Jay M Portnoy8, Jonathan Bernstein9, Derek K Chu10, Chitra Dinakar11, David Golden12, Carolyn Horner13, David M Lang14, Eddy S Lang15, David A Khan16, Jay Lieberman17, David Stukus18, Dana Wallace19.
Abstract
Given the burden of disease and the consequences of a diagnosis of peanut allergy, it is important that peanut allergy be accurately diagnosed so that an appropriate treatment plan can be developed. However, a test that indicates there is peanut sensitization present (eg, a "positive" test) is not always associated with clinical reactivity. This practice parameter addresses the diagnosis of IgE-mediated peanut allergy, both in children and adults, as pertaining to 3 fundamental questions, and based on the systematic reviews and meta-analyses, makes recommendations for the clinician who is evaluating a patient for peanut allergy. These questions relate to when diagnostic tests should be completed, which diagnostic tests to utilize, and the utility (or lack thereof) of diagnostic testing to predict the severity of a future allergic reaction to peanut.Entities:
Keywords: Ara h 2; GRADE analysis; Peanut allergy; cost-effectiveness analysis; diagnosis; evidence to recommendation; likelihood ratio; meta-analysis; peanut components; practice parameter update; serologic IgE testing; skin prick testing; systematic review
Year: 2020 PMID: 32810515 DOI: 10.1016/j.jaci.2020.07.031
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793